What Boxer Capital does

Boxer Capital Management, LLC is a privately-held biotechnology investment firm headquartered in San Diego, California, founded around 2005-2006 by Aaron Davis. The firm operates as a full life cycle investor, deploying capital across private and public markets at every stage of the drug development cycle, with a thematic focus on specialized and precision medicine. The firm has invested in 74 private companies since 2014, participated in 51 liquidity events (IPOs, public listings, and acquisitions), and led or co-led 14 private rounds. Its underlying capability is a research-driven investment process conducted by a team that includes scientists with prior drug discovery and development experience across multiple therapeutic indications, combined with nearly two decades of investment experience.

The firm's business model is based on managing investment capital on behalf of its clients and earning returns through equity appreciation and realized gains on portfolio company exits. It sources deal flow primarily through professional networks and referrals rather than broad marketing, leveraging relationships with biotech founders, executives, and co-investors. Recent activity includes participation in Clene Inc.'s $28 million registered direct offering (January 2026) alongside Coastlands Capital and Vivo Capital, and co-investment in Mirador Therapeutics' $250 million Series B alongside T. Rowe Price, Fidelity, ARCH Venture Partners, OrbiMed, and Adage Capital Partners. The firm does not offer software products or technology platforms; its product is investment capital paired with strategic and scientific guidance to portfolio companies.

The firm was reorganized in 2024 from its predecessor Boxer Capital, LLC into Boxer Capital Management, LLC. Endorsements from former CEOs of Mirati Therapeutics, Prometheus Biosciences, and Pandion Therapeutics (each of which achieved major M&A exits) illustrate the firm's role as a long-term capital partner in successful precision oncology and immunology companies. Boxer Capital does not publicly disclose its AUM, revenue, fee structure, or full investor base.

Name

Boxer Capital

Legal name

Boxer Capital Management, LLC

Website

https://boxercap.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Boxer Capital Management is a San Diego-based private biotech investment firm that invests across the full drug life cycle in precision medicine companies via private and public market equity, serving as a long-term scientific and financial partner to portfolio founders.

Ownership category

akta.pro rank

Product category

Biotechnology Venture Capital

NAICS

Portfolio Management and Investment Advice (52394)

SIC

Investment Advice (6282)

akta.pro primary industry

Large-Cap Equity (Active) (FSAAAIAA)

Keywords

• Biotechnology venture capital
• Precision medicine investing
• Biotech investment management
• Life sciences investment
• Drug development financing

Headquarters

HQ city

Windermere

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Investment Management Fees: Boxer Capital Management operates as a full life cycle investment firm generating returns through equity investments in biotechnology companies across private and public markets. The firm earns returns on its invested capital through liquidity events including IPOs, public access, and acquisitions of portfolio companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Boxer Capital Management is a full life cycle investment firm that provides venture capital and equity investment management to specialized and precision medicine biotechnology companies across private and public markets. The firm invests across all stages of the drug life cycle — from company building and early-stage through late-stage and crossover to public — using a fundamental, research-driven approach staffed by scientists with direct drug discovery experience.

Product overview

Boxer Capital Management is a biotechnology investment firm that provides venture capital and investment management services across private and public markets. The firm does not offer a product-based platform or software services; rather, it offers investment services to its clients. As a venture capital firm, Boxer Capital invests in biotechnology companies across various stages (company building, early-stage, late-stage, crossover private investments to public markets), with a focus on specialized and precision medicine. The firm's offering is structured around investment management services rather than a traditional product portfolio, and it does not have named software products, modules, or technology offerings to enumerate.

Differentiator

Problem solved

Functional benefit

Products and services

• Full Life Cycle Biotechnology Investment Management Fundamental, research-based equity investment management in specialized and precision medicine biotechnology companies across private and public markets, covering company building, early-stage, late-stage, and crossover-to-public investments. Service is provided to the firm's funds and their investors.
• Private Equity Placements in Biotech Ventures Direct equity investments into private biotechnology companies, including participation as lead, co-lead, or co-investor in Series funding rounds, private placements, and structured financings (such as multi-tranche registered direct offerings tied to regulatory milestones).

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Atlas Venture: Boston-based early-stage biotech fund builder with strong scientific orientation; comparable in portfolio construction philosophy to Boxer.
• Venrock Healthcare: Healthcare-focused venture franchise with public-private crossover capabilities; overlaps with Boxer's biotech thesis investing.
• EcoR1 Capital: Biotech-only crossover fund led by scientists/physicians investing across private and public equities; closely comparable to Boxer's specialist model.
• RA Capital Management: Boston-based biotech-focused crossover fund investing across private and public markets with a science-driven diligence approach — directly comparable to Boxer's full life cycle biotech strategy.
• Baker Bros. Advisors: Long-tenured biotech-only investment manager with deep scientific bench; competes with Boxer for precision medicine equity positions across stages.
• OrbiMed: Healthcare-dedicated investment firm across private and public biotech; shares Boxer's specialization and cross-stage deployment model.
• Foresite Capital: San Francisco-based healthcare and biotech specialist with crossover private-to-public investing; comparable in size and scientific thesis orientation.
• ARCH Venture Partners: Early-stage biotech venture firm with deep scientific founder relationships; overlaps with Boxer's early-stage precision medicine focus.
• Perceptive Advisors: Biotech-focused crossover fund deploying across private rounds and public equities; mirrors Boxer's public-private, life-cycle approach.
• 5AM Ventures: Early-stage biotech venture firm with scientist-led diligence; comparable in scale and stage focus to Boxer's early-stage book.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments131 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Boxer Capital